T cell deficiency leads to liver carcinogenesis in azoxymethane-treated rats

Experimental Biology and Medicine

Volumn 231, Issue 1, 2006, Pages 91-98

  Wu, Bin ^a   Ootani, Akifumi ^a,b   Iwakiri, Ryuichi ^a   Sakata, Yasuhisa ^a   Fujise, Takehiro ^a   Amemori, Sadahiro ^a   Yokoyama, Fumie ^a   Tsunada, Seiji ^a   Toda, Shuji ^a   Fujimoto, Kazuma ^a  

^a SAGA UNIVERSITY   (Japan)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinogenesis; Colon; Fos oncogene family; Jun oncogene family; Liver; wt p53

Indexed keywords

AZOXYMETHANE; DNA FRAGMENT; PROTEIN FOS; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CARCINOGENESIS; CELL PROLIFERATION; COLON; COLON CANCER; EVALUATION; IMMUNOASSAY; INCIDENCE; LIVER; LIVER CARCINOGENESIS; LIVER TUMOR; NONHUMAN; ONCOGENE C FOS; PROTEIN EXPRESSION; RAT; RAT STRAIN; T CELL DEPLETION; WESTERN BLOTTING; WILD TYPE;

ANIMALIA;

EID: 30344463284     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/153537020623100111     Document Type: Article

References (58)

1. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725-729, 1996.
2. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281-287, 1999.
3. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738, 2002.
4. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1:209-219, 2001.
5. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2:227-238, 2002.
6. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565-594, 2001.
7. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4RSTAT6 pathway. Nat Immunol 1:515-520, 2000.
8. Sarma S, Guo Y, Guilloux Y, Lee C, Bai XF, Liu Y. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. J Exp Med 189:811-820, 1999.
9. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 186:229-238, 1997.
10. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13:265-276, 2000.
11. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357-2368, 1998.
12. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10:588-594, 1998.
13. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753-756, 1999.
14. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854, 2002.
15. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 250:462-475, 2001.
16. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM. Increased vaccinespecific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163:6292-6300, 1999.
17. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102:849-862, 2000.
18. Jackson-Grusby L, Beard C, Possemato R, Tudor M, Fambrough D, Csankovszki G, Dausman J, Lee P, Wilson C, Lander E, Jaenisch R. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet 27:31-39, 2001.
19. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404:42-49, 2000.
20. Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, Romero F, Arias C, Silva A, Tortolero M, Pintor-Toro JA. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 32:306-311, 2002.
21. Ding HF, Lin YL, McGill G, Juo P, Zhu H, Blenis J, Yuan J, Fisher DE. Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. J Biol Chem 275:38905-38911, 2002.
22. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 264:56-66, 2001.
23. Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van Der Burg SH, Offringa R, Melief CJ. Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 62:6187-6193, 2002.
24. 110-124-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res 63:3675-3681, 2003.
25. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 20:2401-2412, 2001.
26. Vogt PK. Jun, the oncoprotein. Oncogene 20:2365-2377, 2001.
27. Papanikolaou A, Shank RC, Delker DA, Povey A, Cooper DP, Rosenberg DW. Initial levels of azoxymethane-induced DNA methyl adducts are not predictive of tumor susceptibility in inbred mice. Toxicol Appl Pharmacol 150:196-203, 1998.
28. Wu B, Iwakiri R, Tsunada S, Utsumi H, Kojima M, Fujise T, Ootani A, Fujimoto K. iNOS enhances rat intestinal apoptosis after ischemiareperfusion. Free Radic Biol Med 33:649-658, 2002.
29. Wu B, Iwakiri R, Ootani A, Fujise T, Tsunada S, Fujimoto K. Plateletactivating factor promotes mucosal apoptosis via FasL-mediating caspase-9 active pathway in rat small intestine after ischemiareperfusion. FASEB J 17:1156-1158, 2003.
30. Wu B, Ootani A, Iwakiri R, Fujise T, Tsunada S, Toda S, Fujimoto K. Ischemic preconditioning attenuates ischemia/reperfusion-induced mucosal apoptosis by inhibiting the mitochondria-dependent pathway in rat small intestine. Am J Physiol 286:G580-G587, 2004.
31. Wu B, Fujise T, Iwakiri R, Ootani A, Amemori S, Tsunada S, Toda S, Fujimoto K. Venous congestion induces mucosal apoptosis via tumor necrosis factor-alpha-mediated cell death in the rat small intestine. J Gastroenterol 39:1056-1062, 2004.
32. Wu B, Iwakiri R, Ootani A, Tsunada S, Fujise T, Sakata Y, Sakata H, Toda S, Fujimoto K. Long-term dietary corn oil ingestion promotes colon cancer invasion by inhibiting mitochondria-dependent apoptosis in azoxymethane-treated rats. Exp Biol Med 229:1017-1025, 2004.
33. Gallagher SR. One-dimensional electrophoresis using nondenaturing conditions. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, Eds. Current Protocols in Molecular Biology. New York: John Wiley & Sons Inc., part 10.2B.1, pp1-11, 1999.
34. Herr AE, Throckmorton DJ, Davenport AA, Singh AK. On-chip native gel electrophoresis-based immunoassays for tetanus antibody and toxin. Anal Chem 77:585-590, 2005.
35. Seo N, Hayakawa S, Tokura Y. Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells. Semin Cancer Biol 12:291-300, 2002.
36. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 15:749-795, 1997.
37. b molecules expressed on Th2-type γδ T and αβ T cells co-infiltrating in early B16 melanoma lesions. J Immunol 161:4138-4145, 1998.
38. Seo N, Tokura Y, Takigawa M, Egawa K. Depletion of IL-10-and TGF-β-producing regulatory γδ T cells by administering a dounomycin-conjugated specific mAb in early tumor lesions augments the activity of CTLs and NK cells. J Immunol 163:242-249, 1999.
39. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245-273, 2000.
40. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12:2973-2983, 1998.
41. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell 95:5-8, 1998.
42. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287:1824-1827, 2000.
43. Sharpless NE, DePinho RA. p53: good cop/bad cop. Cell 110:9-12, 2002.
44. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1:45-49, 1992.
45. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53. Cell 112:29-40, 2003.
46. Hu Y, Le Leu RK, Young GP. Absence of acute apoptotic response to genotoxic carcinogens in p53-deficient mice is associated with increased susceptibility to azoxymethane-induced colon tumours. Int J Cancer 115:561-567, 2005.
47. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607-614, 2002.
48. Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell 120:7-10, 2005.
49. Shivapurkar N, Belinsky SA, Wolf DC, Tang Z, Alabaster O. Absence of p53 gene mutations in rat colon carcinomas induced by azoxymethane. Cancer Lett 96:63-70, 1995.
50. Erdman SH, Wu HD, Hixson LJ, Ahnen DJ, Gerner EW. Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethaneand dimethylhydrazine- treated rats. Mol Carcinog 19:137-144, 1997.
51. Nambiar PR, Giardina C, Guda K, Aizu W, Raja R, Rosenberg DW. Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model. Cancer Res 62:3667-3674, 2002.
52. Cicinnati VR, Dworacki G, Albers A, Beckebaum S, Tuting T, Kaczmarek E, DeLeo AB. Impact of p53-based immunization on primary chemically-induced tumors. Int J Cancer 113:961-970, 2005.
53. Kuball J, Schmitz FW, Voss RH, Ferreira EA, Engel R, Guillaume P, Strand S, Romero P, Huber C, Sherman LA, Theobald M. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 22:117-129, 2005.
54. Johnson R, Spiegelman B, Hanahan D, Wisdom R. Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol 16:4504-4511, 1996.
55. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, Karin M, Angel P, Wagner EF. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 13:607-619, 1999.
56. Wang ZY, Sato H, Kusam S, Sehra S, Toney LM, Dent AL. Regulation of IL-10 gene expression in th2 cells by jun proteins. J Immunol 174:2098-2105, 2005.
57. Ordway JM, Williams K, Curran T. Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene 23:3737-3748, 2004.
58. Holmes DI, Zachary I. Placental growth factor induces FosB and c-Fos gene expression via Flt-1 receptors. FEBS Lett 557:93-98, 2004.